HomeLatest NewsFederal NewsNIH Research Highlights Increased Post-COVID-19 Risk of Pediatric Diabetes, Pfizer Vaccine’s Effectiveness...

NIH Research Highlights Increased Post-COVID-19 Risk of Pediatric Diabetes, Pfizer Vaccine’s Effectiveness in Preventing MIS-C in Adolescents and Teens

​The National Institutes of Health last week released a pair of studies offering fresh insights into COVID-19’s long-term effect on pediatric groups. The first study evaluates the effectiveness of Pfizer’s COVID-19 vaccine as a mean for preventing multisystem inflammatory syndrome in children, more commonly known as “MIS-C.” Researchers found that the Pfizer vaccine, when used for individuals between the ages of 12 and 18, was 91% effective in preventing MIS-C, which is observed to occur two to six weeks after SARS-CoV-2 infection and can be fatal in some cases. According to the study, among critically ill MIS-C case-patients who required life support, all were unvaccinated.
A second study suggests an increased risk of children developing diabetes following a COVID-19 infection. Researchers after reviewing data from the IQVIA and HealthVerity databases found that patients under the age of 18 were more likely to receive new diabetes diagnoses, beginning 31 days following a COVID-19 infection. The researchers said these findings are consistent with previous research demonstrating an association between SARS-CoV-2 infection and diabetes in adults.

Stay Connected

Unified Voice Newsletter

Events This Month


20may11:00 am12:00 pmAddressing Public Misperceptions About Palliative Care

21may12:00 pm1:00 pmTrauma-Informed Care: Why It’s Important and How to Implement It into PracticeCAPC Webinar

21may12:00 pm1:00 pmFinance Fundamentals for Hospitals (Hospital Financial series Part 2)SDAHO Webinar

22may12:00 pm1:00 pmLTC Town Hall: Understanding Enhanced Barrier PrecautionsWebinar

23may12:00 pm1:30 pmInfection Prevention: Guiding Hospitals Toward Effective, Compliant, and Sustainable SolutionsSDAHO Webinar

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact